Headlines about Editas Medicine (NASDAQ:EDIT) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Editas Medicine earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.1067463875545 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Editas Medicine, Inc. (EDIT), Puma Biotechnology, Inc. (PBYI) (currenthollywood.com)
- Broncos DE Billy Winn Out For Season (trikkles.com)
- Oppenheimer Reiterates a Hold Rating on Editas Medicine Inc (newstrendstoday.com)
- Shares Of Editas Medicine, Inc. (EDIT) bought By NIKOLIC BORIS (leisuretravelaid.com)
- Editas Medicine, Inc. (NasdaqGS:EDIT) and TC PipeLines, LP (NYSE:TCP): How Do These Stocks Rank Value-Wise? – Evergreen Caller (evergreencaller.com)
A number of equities research analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a report on Tuesday, July 18th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Thursday. SunTrust Banks, Inc. started coverage on shares of Editas Medicine in a report on Thursday, July 13th. They set a “hold” rating and a $17.00 target price for the company. J P Morgan Chase & Co set a $27.00 price target on shares of Editas Medicine and gave the company a “hold” rating in a research report on Wednesday. Finally, Zacks Investment Research cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.03.
Shares of Editas Medicine (EDIT) traded up 11.31% on Friday, hitting $21.95. 1,767,150 shares of the stock traded hands. The firm’s 50 day moving average is $17.20 and its 200-day moving average is $19.02. Editas Medicine has a 12 month low of $12.43 and a 12 month high of $29.20. The company’s market cap is $898.33 million.
Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.01. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $2.20 million. Editas Medicine had a negative return on equity of 69.21% and a negative net margin of 2,091.36%. The company’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.54) EPS. Equities analysts predict that Editas Medicine will post ($2.84) earnings per share for the current year.
In related news, insider Gerald Frank Cox acquired 4,000 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was purchased at an average price of $14.15 per share, for a total transaction of $56,600.00. Following the transaction, the insider now owns 4,000 shares in the company, valued at approximately $56,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Bitterman sold 1,000,000 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $17.00, for a total value of $17,000,000.00. The disclosure for this sale can be found here.
COPYRIGHT VIOLATION WARNING: “Editas Medicine (NASDAQ:EDIT) Getting Somewhat Positive Press Coverage, Analysis Finds” was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.baseball-news-blog.com/2017/08/14/editas-medicine-nasdaqedit-earning-somewhat-positive-news-coverage-report-finds-updated-updated-updated.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.